Skip to main content

Scientific Insights that Accelerate Drug Development

Are you feeling daunted by the task of planning your drug’s clinical development? The need to understand how to optimize safety and efficacy in drug development is critical to your program. The good news is, you’ve certainly come to the right place. In Raj’s Corner, we’ve assembled a series of expert blog posts that will explain best practices that support the most streamlined and informative clinical development program. Pharmaceutical innovation comes at a massive cost, cost to the drug developer but also cost in making the right choices and decisions. As new targets are mined, there is an increasing challenge to ensure there is "druggability" – are the targets tractable and is there biological plausibility Dr. Rajesh Krishna is currently a Distinguished Scientist in Drug Development Science. He has more than 20 years of drug development experience with past leadership roles in product value enhancement and quantitative clinical pharmacology at Merck, Aventis, and Bristol-Myers Squibb.
Contact Us


rajesh krishna (1)

Rajesh Krishna

Rajesh Krishna, PhD, is a Distinguished Scientist in Drug Development Science.  Rajesh came to Certara after a rich 20+ years of pharmaceutical industry experience in translational and clinical development at Merck, Sanofi (legacy Aventis), and Bristol-Myers Squibb.  He has contributed to 40+ INDs, more than 200 Phase 1/1b studies; and to the worldwide registration of 9 new molecular entities.

How Can We Help?